Skip to content
OpenCapital
Get started

enGene Therapeutics Inc. ENGN Q2 2026 earnings

Reported June 15, 2026 · Before market open

EPS-$0.43Beat by $0.05
EPS estimate-$0.48

Next report

Sep 14, 2026 (in a month)
EPS estimate-$0.47

Versus estimates

Diluted EPS

Q2 2026-$0.43Beat by $0.05
Q1 2026-$0.44Beat by $0.11Q4 2025-$0.73Miss by $0.16Q3 2025-$0.57Miss by $0.07Q2 2025-$0.51Miss by $0.01Q1 2025-$0.48Miss by $0.11

Ask the moment enGene Therapeutics Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did enGene Therapeutics Inc. report Q2 2026 earnings?
enGene Therapeutics Inc. (ENGN) reported Q2 2026 earnings on June 15, 2026 before market open.
What were enGene Therapeutics Inc. 's Q2 2026 revenue and EPS?
enGene Therapeutics Inc. reported eps of $-0.43 for Q2 2026.
Did enGene Therapeutics Inc. beat estimates in Q2 2026?
EPS beat the consensus estimate of $-0.48 by $0.05.
How did enGene Therapeutics Inc. 's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 15.7% from $-0.51.
Where can I find enGene Therapeutics Inc. 's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-270384) and the 10-Q periodic report (0001193125-26-270386) directly on SEC EDGAR. The filing index links above go to sec.gov.